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Abstract
Aim
Cardiac inflammation is important in the pathogenesis of heart failure. However, the conse-
quence of systemic inflammation on concomitant established heart failure, and in particular
diastolic heart failure, is less explored. Here we investigated the impact of systemic inflam-
mation, caused by sustained Toll-like receptor 9 activation, on established diastolic heart
failure.
Methods and Results
Diastolic heart failure was established in 8–10 week old cardiomyocyte specific, inducible
SERCA2a knock out (i.e., SERCA2a KO) C57Bl/6Jmice. Four weeks after conditional KO,
mice were randomized to receive Toll-like receptor 9 agonist (CpG B; 2μg/g body weight) or
PBS every third day. After additional four weeks, echocardiography, phase contrast mag-
netic resonance imaging, histology, flow cytometry, and cardiac RNA analyses were per-
formed. A subgroup was followed, registering morbidity and death. Non-heart failure control
groups treated with CpG B or PBS served as controls. Our main findings were: (i) Toll-like
receptor 9 activation (CpG B) reduced life expectancy in SERCA2a KOmice compared to
PBS treated SERCA2a KOmice. (ii) Diastolic function was lower in SERCA2a KOmice
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with Toll-like receptor 9 activation. (iii) Toll-like receptor 9 stimulated SERCA2a KOmice
also had increased cardiac and systemic inflammation.
Conclusion
Sustained activation of Toll-like receptor 9 causes cardiac and systemic inflammation, and
deterioration of SERCA2a depletion-mediated diastolic heart failure.
Introduction
Heart failure (HF) is a major cause of morbidity and mortality worldwide with an overall prev-
alence of about 2–3% [1]. Although major improvements have been made in the management
of HF, there is still an imminent need for novel treatment strategies. To achieve this, more
knowledge of the pathogenic mechanisms is needed including identification of central patho-
genic molecular players involved in the development and progression of this disorder.
Activation of the innate immune system is an important pathogenic mechanism in HF
[2,3,4]. The innate immune system consists of pattern recognition receptors (PRRs) that are
activated by evolutionary conserved microbial structures denominated pathogen associated
molecular patterns (PAMPs). Importantly, PRRs also recognize self-antigens i.e., damage
associated molecular patterns (DAMPs), which are released upon cellular stress or death [5].
Upon PRR activation, a robust inflammatory response is seen with the induction of a plethora
of cytokines and adhesion molecules and subsequent mobilization of leukocytes into inflamed
tissue [6].
PRRs are divided into two large families; cytosolic and membrane-bound, where Toll-like
receptors (TLRs) represent the largest subfamily within the latter [7]. One particularly interest-
ing PRR within the TLR group is Toll-like receptor 9 (TLR9). TLR9 was first identified as a
PRR recognizing Cytosine-phosphate-Guanine (CpG) repeats within microbial DNA [8].
Importantly, recent data has demonstrated that endogenous mitochondrial DNA (mtDNA) is
a DAMP, activating TLR9 [9,10,11]. Synthetic oligodeoxynucleotides bearing CpG motifs
(CpG ODNs) activate TLR9 like unmethylated CpG motifs in bacterial DNA [12]. CpG ODNs
can be classified into four classes, including type B CpG ODNs (CpG B), which are potent acti-
vators of B-cells, dendritic cells and macrophages [13]. We have recently confirmed TLR9 spec-
ificity in murine cardiac fibroblasts exposed to CpG B with or without the presence of the
TLR9 inhibitor, ODN 2088 or the inhibitor of endosomal acidification, chloroquine diphos-
phate [14]. Moreover, others and we have demonstrated that both acute and sustained TLR9
activation with CpG B mediate systemic inflammation [15,16], and TLR9 activation has also
been linked to development of myocardial failure [2,3,17]. However, the effect of sustained sys-
temic TLR9 activation on the myocardial structure and function is not clear.
The sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) is the nodal protein governing
active diastolic function [18]. We have previously published data showing that cardiomyocyte
specific deletion of SERCA2a leads to diastolic HF [19]. Although clinical diastolic HF is a mul-
tifactorial disease including abnormalities both in active relaxation and passive “stiffness” [20],
abnormalities in SERCA2a function is a central entity. Thus, a murine model with cardiomyo-
cyte specific deletion of SERCA2a can be considered a reliable model of diastolic HF in vivo.
Experimental models have shown that altered TLR9 signalling may influence the clinical pro-
gression of systolicHF, though the results are ambiguous, partly reflecting differences in experi-
mental models [2,3,17]. Thus, while systemic administration of a TLR9 agonist inhibited
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cardiac hypertrophy and dysfunction in isoproterenol and pressure overload-induced cardio-
myopathy [3,17], TLR9 activation restricted to the cardiomyocyte leads to aggravated HF, this
noteworthy also in pressure overload induced cardiomyopathy [2]. Obviously, the consequence
of systemic TLR9 activation in HF is not studied at all in diastolic HF, representing a specific
pathogenic entity as compared with systolic HF.
The main aim of this study was therefore to investigate the impact of sustained TLR9 stimu-
lation using a specific TLR9 agonist, namely the CpG B, ODN 1688 in a model of murine dia-
stolic HF i.e. SERCA2a knock out (KO).
Methods
2.1. Ethics
All animals were cared for according to the Norwegian Animal Welfare Act, which conforms
to the National Institutes of Health guidelines (NIH publication no. 85–23, revised 1996).
Experiments were approved by the Norwegian National Animal Research Committee (FOTS
application 5319). Up to six mice were kept in each cage and housed in a temperature-regu-
lated room with a 12:12-hours day-night cycling and had free access to food and water ad libi-
tum. To reduce animal suffering and distress mice were observed daily, registering morbidity
and spontaneous death according to pre-specified criteria (leading to euthanization). See S1
Table. During echocardiography and PC- MRI mice were placed in a supine position on a
heated pad to ensure stable conditions, anesthetized in a mixture of oxygen and 1.5–1.75% iso-
flurane and euthanized during deep anesthesia in a mixture of oxygen and 4–5% isoflurane.
See Supporting Information for details. An experienced operator did euthanization with a
quick cervical dislocation, while the remaining animals were found spontaneously dead. Five
control CpG B mice lived throughout the study.
2.2. Induction of experimental HF and systemic inflammation
We have previously described the generation of gene-targeted mice with C57Bl/6J background,
allowing temporal control (by tamoxifen induced expression of Cre) of cardiac myocyte spe-
cific SERCA2a gene-deletion (αMHC-MerCreMer-SERCA2aflox/flox) [21]. Gene-targeted mice
and control mice (αMHC-MerCreMer) were generated from the same founder animals. Male
mice (aged 8–10 weeks) were intraperitoneally (i.p.) injected with one single-dose of 100 μl
tamoxifen [22] (T5648; Sigma Aldrich, Oslo, Norway dissolved in peanut oil to a concentration
of 10 mg/ml) inducing nuclear translocation of MerCreMer, but only causing SERCA2a gene-
deletion in αMHC-MerCreMer-SERCA2aflox/flox mice. Four weeks after injection of tamoxifen,
αMHC-MerCreMer-SERCA2aflox/flox and αMHC-MerCreMer mice (hereafter denominated
SERCA2a KO and controls) were randomized to receive 100μl i.p. injections of the TLR9 ago-
nist CpG B (ODN 1668 Class B, 2μg/g body weight, Invivogen, San Diego, CA) or vehicle
(PBS) every third day. Mice were divided into two substudies: 1) One cohort in which mice
were followed for additional 4 weeks while receiving injections of TLR9 agonist or vehicle as
described. When reaching 4 weeks after initiation of CpG B or vehicle treatment (i.e., 8 weeks
after tamoxifen injection), echocardiography and phase contrast magnetic resonance imaging
(PC-MRI) analyses were performed with subsequent euthanization by extirpation of the heart.
Tissues (heart, lung, spleen, liver) and blood were harvested for further analyses. This renders a
total duration of 8 weeks from SERCA2a gene-deletion to harvesting of organs. 2) A second
cohort of mice was observed daily by an investigator blinded to genotype and intervention, reg-
istering morbidity and spontaneous death according to pre-specified criteria (leading to eutha-
nization). Further details are provided in S1 Table.
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2.3. Cardiac imaging
At 8 weeks after SERCA2a gene-deletion, in vivo heart function was evaluated by echocardiog-
raphy (n = 6–12 per group) with mice placed in a supine position on a heated pad to ensure sta-
ble conditions. To keep the variations in cardiodepressive effects to a minimum, anesthesia was
standardized and maintained during the procedure with a mixture of 1.75% isoflurane and
98.25% oxygen on a mask while spontaneously breathing. Echocardiographic examinations
were performed with a Vevo2100 (VisualSonics, Toronto, Canada) using a 35 MHz linear
array transducer (VisualSonics). Recorded data were analyzed off-line using the VEVO 2100
1.1.0 software (VisualSonics) [23]. Apart from left ventricle ejection fraction (LVEF) and left
ventricle fractional shortening (LVFS) echocardiographic parameters were corrected for tibia
length (TL). The duration of the procedure was no longer than 10 minutes per animal and all
mice recovered from anesthesia within 1–2 min. As a supplement to echocardiographic mea-
surements of cardiac dimensions and function, and to assess diastolic function, we performed
PC-MRI using a 9.4T pre-clinical MR system (Agilent Technologies, Inc., Palo Alto, CA) with
high-performance gradient (60 mm ID, rise time 130 μs, max strength 100 gauss/cm) and a
quadrature volume RF coils (35 mm ID, Rapid Biomedical) dedicated to mouse imaging
(n = 5–7 per group) [24]. Our group has previously assessed diastolic function in SERCA2a
KO mice by the time constant of isovolumetric pressure decay (tau) [18]. However, as PC-MRI
is a non-invasive method and thus more accurate and beneficial to evaluate physiological
changes, we preferred to use this method for measurement of cardiac function in vivo. All car-
diac imaging was recorded by an investigator blinded to the treatment groups. See Supporting
Information for details.
2.4. Morphological assessment of tissue inflammation
Eight weeks after SERCA2a deletion and PC-MRI measurements, mice were euthanized during
deep anesthesia in a mixture of 4–5% isoflurane and oxygen while organs (heart, lung and
liver) were extirpated and rinsed in saline. A standardized 2 mm slice was taken from the hearts
(n = 5–8) using a mouse heart slicer matrix (Zivic instruments, Pittsburgh, PA). The heart
slice, the right lung middle lobe from hilum (n = 7–11) and the liver left lateral lobe (n = 7–10)
were fixated in 4% formalin, embedded in paraffin, sectioned at 3 μm, mounted on glass slides
and stained with haematoxylin and eosin (HE). A trained pathologist, blinded to the mouse
genotype and intervention, visually assessed the degree of inflammation and tissue injury
according to a pre-specified scoring system in hearts as well as in peripheral organs (lungs and
livers). See S2 Table for details.
2.5. Quantification of cardiac monocyte/macrophage infiltration and
fibrosis
Sections (n = 5–8 per group) of formalin-fixed and paraffin-embedded heart slices were depar-
affinized by immersing slides in fresh xylene with subsequent hydration processing followed by
96°C unmasking in citrate buffer (pH 6) for 20 min. Blocking was performed using Rodent
block M (Biocare Medical, Concord, CA) followed by one-hour incubation with primary anti-
body against macrophages (MAC-2; monoclonal rat anti-mouse, clone M3/38, IgG2A dilution
1:200; Cedarlane, Burlington, ON, Canada) at room temperature. After washing, slides were
incubated 30 min with peroxidase-conjugated secondary antibody (ImmPRESS Anti-Rat Ig;
Vector Laboratories, Burlingame, CA) at room temperature. Sections were developed for 8 min
with chromogen for immune peroxidase staining (DAB,Vector Laboratories), before counter-
staining with Haematoxylin QS (Vector Laboratories).
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To quantify the amount of MAC-2 stained cells, histological slides were examined using a
Nikon Eclipse E400 microscope with 40x objective. The images were automatically stitched
using Hugin Panorama Photo Stitcher (Hugin 2013,http://hugin.sourceforge.net) to form a
complete rendering of the slide. Prior to the analysis, the investigator was blinded to the
groups. Using ImageJ (version 1.49, National Institutes of Health, Bethesda, MD) the images
were thresholded using three-color channels adapted to the target stain. Manual removal of
artifacts, any obvious areas of non-cardiac tissues along with the exclusion of the area of the
section corresponding to the right ventricle was performed prior to measurement of the stained
area. The stained area was adjusted for the total area of the section resulting in a relative quan-
tification of the amount of MAC-2 stained cells.
As a measure of total myocardial collagen content, quantitative analysis of tissue contents of
hydroxyproline was performed by HPLC using the AccQ-Fluor reagent kit (Waters Corpora-
tion Milford, MA, USA) as previously described [25].
2.6. RNA isolation cDNA synthesis and quantitative RT-PCR (qPCR)
Total RNA (n = 7–12 per group) was isolated from LV myocardial tissue by pre-processing
with TRIzol reagent (Applied Biosystems, Foster City, CA). To ensure optimal RNA quality
subsequent standard isolation using RNeasy Mini Kit (Qiagen, Venlo, The Netherlands) were
performed. All RNA samples were stored at -80°C until analyzed. cDNA was synthesized using
the High Capacity cDNA Reverse Transcription Kit from Applied Biosystems. PCR reactions
were set up in 384 well plates using Eppendorf epMotion (Eppendorf, Hauppauge, NY). Target
genes were amplified using the Power SYBR Green Master Mix (Invitrogen Life Technologies
Corporation, Carlsbad, CA) and by using Applied Biosystems 7900HT Fast Real-Time PCR
system. Target gene expression was normalized to glyceraldehyde 3-phosphate dehydrogenase
(GAPDH). Primer sequences used for analyzing inflammatory cytokines and chemokines are
provided in S3 Table.
2.7. Assessment of circulatory inflammatory cells
Flow cytometry (n = 6–12 per group) of circulating blood cells was performed as previously
described [16]. In short, upon euthanization arterial blood (approximately 700–1000 μl) was
collected at 8 weeks after SERCA2a gene deletion (by a small incision of the carotid artery) into
tubes containing 50μl of EDTA 0.5M. Twenty-four hours later, 100 μl whole-blood was blocked
using Mouse BD Fc Block (BD Biosciences, San Jose, CA) before labeling with 2.5μl (0.2 mg/
ml) CD11b-APC and Ly6G-PE or 1.0μl (0.5mg/ml) CD3e-FITC with subsequent lysis of red
blood cells. Flow cytometry analysis was performed blinded to the treatment groups, using
FACSCalibur (BD Biosciences).
2.8. Statistical analyses
Unpaired data were evaluated using Graphpad Prism 6 (GraphPad, San Diego, CA), ANOVA
Kruskal Wallis test, and subsequent Mann-Whitney non-parametric test for comparison of
two groups. Survival analysis was performed using Log rank (Mantel Cox test). Results are
shown as mean±SEM. To compare the distribution of score numbers between the groups after
scoring inflammation in heart-, lung- and liver tissue, we used IBM SPSS Statistics (version 22)
Chi square test. Probability values of P<0.05 were considered significant.
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Results
3.1. Systemic TLR9 activation leads to premature death in SERCA2a
KO induced diastolic HF
All the animals reached our pre-specified end-parameter (death or euthanasia according to pre-
specified criteria) after induction of cardiomyocyte-specific deletion of the SERCA2a gene. Of the
40 mice (SERCA2a KO PBS n = 16; SERCA2a CpG B n = 19; Control CpG B n = 5), 9 animals
were euthanized due to objective pre-specified criteria of distress indicating severe HF (SERCA2a
KO PBS n = 2; SERCA2a KO CpG B n = 7). There was a non-significant trend towards a higher
proportion of CpG B treated SERCA2a KOmice euthanized (p = 0.13, Fischer’s exact test). We
found reduced life expectancy in TLR9 stimulated SERCA2a KOmice compared with PBS
treated SERCA2a KOmice (median 59 vs. 64.5 days, respectively, p = 0.004). Importantly, this
was also significant when excluding mice that were euthanized (p<0.01). Within the observation
period, there was no mortality or clinical morbidity in TLR9 stimulated control mice (Fig 1A).
3.2. TLR9 stimulation deteriorated diastolic function in SERCA2a KO
mice
Echocardiography and PC-MRI was performed 4 weeks after initiation of CpG B or vehicle treat-
ment and 8 weeks after cardiomyocyte-specific deletion of the SERCA2a gene. Results are dis-
played in Tables 1 and 2. As the impairment of active relaxation caused by SERCA2a depletion
commences, the ability to increase chamber size during diastole is severely restrained causing a
lower LV inner diastolic diameter (LVID;d), subsequently necessitating a lower LV inner systolic
diameter (LVID;s) in attempt to maintain stroke volume. Upon sustained TLR9 stimulation, these
parameters were significantly worsened (Fig 1B and 1C). Another major echocardiographic phe-
notype of SERCA2a KOmice is enlargement of the left atrium (LA), a consequence of the diastolic
HF causing increased LV filling pressure. In this study, TLR9 stimulated SERCA2a KOmice had
significantly larger LA compared with PBS treated SERCA2a KOmice, further suggesting aggrava-
tion of the diastolic impairment (Fig 1D). In corroboration with these results, PC-MRI analyses
showed decrease in the early ventricular filling velocity (e’) in SERCA2a KOmice, which was sig-
nificantly worsened when challenged with sustained TLR9 stimulation (Fig 1E). In contrast to the
worsening of diastolic function, TLR9 activation resulted in increased LVEF (Table 1) and LVFS
(Fig 1F). The latter are observations we have described previously and suggested partly being
mediated by altered intracellular contents of sodium [19]. Indeed, in other cardiac clinical condi-
tions associated with reduced cardiac dimensions (like hypertrophic cardiomyopathy or severe
aortic stenosis), increased LVFS and LVEF are seen [19,21]. In fact, long axis strain, assessed by
PC-MRI, showed that SERCA2a KOmice in the later phases of HF development (8 weeks) display
reduced axial shortening (Fig 1G), albeit with no significant effect of TLR9 activation. There were
no significant differences in heart and body weights between the groups (S4 Table). However,
CpG B treated SERCA2a KOmice demonstrated increased relative wall thickness (RWT)
(Table 1). As the SERCA 2a KO phenotype is driven by an active relaxation deficit, the RWT does
not reflect actual hypertrophy but in fact a reduction in LVID;d due to a reduction of the heart
size in total. Thus, the impairments in cardiac function promoted by sustained TLR9 stimulation
in SERCA2a KOmice seem to be predominantly driven by aggravations in diastolic function.
3.3. Sustained TLR9 stimulation augments cardiac inflammation and
fibrosis in SERCA2a KO induced HF
Cardiac inflammation was assessed by histopathological staging, quantification of cardiac
monocyte/macrophage infiltration and by assessing cytokine gene expression. The
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Fig 1. Increasedmortality and deteriorated cardiac functions and structures in TLR9 stimulated (CpG B) SERCA2A KOmice 8 weeks after gene
excision and 4 weeks after initiation of sustained TLR9 stimulation. (A) Survival analysis: median 59 days in TLR9 stimulated SERCA2a KOmice vs.
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histopathological staging was performed using a simple three/four-point score visual assess-
ment of cardiac myocyte stress and or/death (nuclear-to-cytoplasm ratio and vacuolization or
necrotic muscle fibers) as well as quantification of cardiac leukocyte infiltration. Several signifi-
cant findings were revealed. First, signs of cardiac myocyte stress and/or death were seen in
TLR9 stimulated control mice. Also, a higher degree of this phenomenon could be seen in SER-
CA2a KO hearts compared to PBS control mice. Although, the combination of SERCA2a KO
and TLR9 stimulation appeared additive, it was not significantly different to SERCA2a KO
alone (Fig 2A and 2B). Second, TLR9 stimulation increased leukocyte infiltration as assessed
by primarily lymphocytes in both control and SERCA2a KO mice, with no difference between
the genotypes (Fig 2C). Third, in contrast to lymphocyte infiltration, a significantly higher car-
diac infiltration of monocytes/macrophages was seen in TLR9 stimulated SERCA2a KO mice
compared with both TLR9 stimulated control mice and PBS treated SERCA2a KO mice (Fig
3A and 3B). Finally, whereas SERCA2a KO hearts did not display significant alterations in the
chosen inflammatory genes, sustained TLR9 stimulation induced a significant up-regulation of
CXCL10, CXCL2, CCL2 and TNF in these mice (Fig 4A–4D).
As increased inflammatory cells were detected in TLR9 stimulated hearts, we assessed car-
diac fibrosis as a potential cause of diastolic dysfunction. Measurements of hydroxyproline in
LV myocardial tissue samples of TLR9 stimulated SERCA2a KO hearts demonstrated a trend
64.5 days in SERCA2a KO. Groups were compared using Log rank (Mantel Cox test, n = 16–19 per group, n = 5 in TLR9 stimulated control group). (B) LV
inner diastolic diameter/TL (LVID;d, mm). (C) LV inner systolic diameter/TL (LVID;s, mm). (D) Left atrium/TL (mm). (E) Early ventricular filling velocity (e’) (F)
LV fractional shortening (LVFS%) (G) Longitudinal strain (%). LVID (B and C), left atrium (D) and LVFS (F) were determined using echocardiography
(n = 6–12 per group), and e’ (E) and longitudinal strain (G) were determined using PC-MRI (n = 5–7 per group). TL, tibia length (mm). Statistics were done
using MannWhitney U- test. Data are mean± SEM. *P<0.05, **P <0.01, ***P<0.001 vs. SERCA2a KOmice. #P<0.05, ##P<0.01, ###P<0.001 vs. control with
same intervention.
doi:10.1371/journal.pone.0139715.g001
Table 1. Echocardiographic parameters in SERCA2a KO and control mice 8 weeks after gene excision and 4 weeks after initiation of sustained
TLR9 stimulation.
Controls SERCA2a KO
PBS (n = 6) CpG B (n = 8) PBS (n = 12) CpG B (n = 9)
LVEF (%) 40.5 ± 12.4 43.7 ± 12.0 41.2 ± 5.0 49.6 ± 8.0 *
CO (ml/min)/ TL 1.4 ± 0.2 2.2 ± 0.8 1.0 ± 0.3 1.0 ± 0.6 ##
SV (ml)/TL 3.2 ± 0.1 4.0 ± 1.1 2.3 ± 0.6 ### 1.9 ± 0.7 ##
IVS;d (mm)/TL 0.05 ± 0.005 0.04 ± 0.009 0.04 ± 0.004 0.05± 0.006
IVS;s (mm)/TL 0.06 ± 0.009 0.06 ± 0.010 0.05 ± 0.007 0.06 ± 0.007
LVPW;d (mm)/TL 0.05 ± 0.010 0.04 ± 0.006 0.05 ± 0.010 0.04 ± 0.006
LVPW;s (mm)/TL 0.06 ± 0.014 0.05 ± 0.008 0.054 ± 0.008 0.06 ± 0.010
LVvol;d (μL)/TL 4.9 ± 0.8 4.6 ± 0.6 3.6 ± 0.5 2.7 ± 0.6 *
LVvol;s (μL)/TL 3.0 ± 0.8 2.6 ± 0.8 2.1 ± 0.3 1.4 ± 0.4 *
RWT 0.39 ± 0.038 0.37 ± 0.042 0.43± 0.064 0.51 ± 0.105 ##
Heart rate (BPM) 467.4 ± 55.8 488.6 ± 54.5 452.5 ± 44.2 428.4 ± 57.6 #
LV, Left ventricle; EF, Ejection fraction; CO, Cardiac output; SV, Stroke volume; d, diastolic; s, systolic; TL, Tibia length (mm); IVS, inter ventricular septum
thickness; LVPW, LV posterior wall thickness; LVvol, LV volume; RWT, relative wall thickness (Formula: IVS;d+LVPW;d/ LVID;d); Data are expressed as
the mean±SD.
*P<0.05 vs. SERCA2a KO mice.
#P<0.05
##P<0.01
###P<0.001 vs. control with same intervention.
doi:10.1371/journal.pone.0139715.t001
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towards increased collagen deposition (p = 0.07). This trend, however, was supported by
increased collagen I (p = 0.19) and III (p = 0.07) mRNA gene expressions (Fig 5).)
Taken together, these data do provide evidence of cardiac inflammation upon sustained,
systemic TLR9 stimulation with enhanced monocyte/macrophage infiltration and possibly
increased fibrosis in TLR9 stimulated SERCA2a KO mice as a pathomechanistic explanation
for the deteriorated diastolic function.
3.4. Both HF and sustained TLR9 stimulation promote systemic
inflammation
Both HF (SERCA2a KO) [2] and repetitive administrations of a TLR9 agonist (i.e., CpG B)
could promote inflammation in non-cardiac organs [15]. Thus, we assessed the inflammatory
responses in lung, liver and circulatory immune cells in mice with combinations of those two
conditions. Using flow cytometry, we analyzed circulating levels of monocytes (CD11b positive
cells), T cells (CD3 positive cells) and granulocytes (Ly6G positive cells) and found no signifi-
cant alterations in SERCA2a KO mice compared to controls (Fig 6A–6C). As previously
reported [15], sustained TLR9 stimulation induced leukopenia with lower amounts of CD11b
and CD3 positive cells in TLR9 stimulated control mice (Fig 6A and 6B). In contrast, TLR9
stimulated SERCA2a KO mice showed a higher level of CD11b (p = 0.06) and CD3 (p = 0.03)
positive cells than seen in both PBS treated SERCA2a mice and TLR9 stimulated control mice
(Fig 6A and 6B). As for the distribution of Ly6G positive cells, no significant differences could
be seen between any groups (Fig 6C).
Histopathological staging, using pre-defined histological criteria as viewed in S2 Table, was
used to assess degree of liver and lung inflammation. Even though we did find a significantly higher
wet lung weight in SERCA2a KOmice challenged with sustained TLR9 stimulation, no effect of
CpG B stimulation was evident in histopathological staining in either SERCA2a KO or control
mice. We did not see any histopathological signs of lung edema. A robust pulmonary inflamma-
tory response, however, could be seen in SERCA2a KOmice with no further effect of TLR9 (S1
Fig, Fig 7A). In contrast, histopathological staging of liver inflammation revealed a significant alter-
ation in mice challenged with TLR9 stimulation with increased lymphocytes in both SERCA2a KO
and control mice (S2 Fig, S3 Fig), accompanied by significantly increased liver weights (Fig 7B).
Discussion
Most studies on HF focus on aspects related to intrinsic cardiac mechanisms of evolving heart
dysfunction. However, HF patients often suffer from co-morbidities with inflammation as the
Table 2. Phase contrast magnetic resonance imaging in SERCA2A KO and control mice 8 weeks after gene excision and 4 weeks after initiation of
sustained TLR9 stimulation.
Controls SERCA2a KO
PBS (n = 6–8) CpG B (n = 7–8) PBS (n = 7–8) CpG B (n = 5–6)
Late ventricular ﬁlling velocity;a’ (1/s) 5.9 ± 2.4 3.8 ± 1.0 4.8 ± 2.0 3.5 ± 0.5
Long.strain rate;s (1/s) -4.9 ± 0.8 -4.7 ± 1.3 -4.1 ± 1.1 -3.7 ± 1.1
Max.rad velocity (cm/s) 1.0 ± 0.5 1.3 ± 0.3 1.0 ± 0.3 0.81 ± 0.16
Min.rad velocity (cm/s) -1.6 ± 0.3 -1.7 ± 0.4 0–1.2 ± 0.2 -1.0 ± 0.3
Circ.strain (%) -14.9 ± 2.3 15.2 ± 2.9 -12.0 ± 1.6 -9.3 ± 3.4
Long.strain rate, Longitudinal strain rate; Max.rad velocity, Maximum radial velocity; Min. Rad velocity, Minimum radial velocity; Circ.strain, Circumferential
strain. Data are expressed as mean±SD.
doi:10.1371/journal.pone.0139715.t002
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Fig 2. Histology of haematoxylin and eosin stained hearts. (A) Photos taken with 40x objective (scale bar 50μm). (A-B) Cardiac cell stress and/or death:
increased nucleus-to-cytoplasm ratio (light blue arrow), swollen cardiomyocyte cytoplasm (dark blue arrow), vacuolization (red arrow), cardiac cell death
(green arrow). (A-C) Interstitial leukocyte infiltration (black arrow). See S2 Table for details. Distribution between the groups was compared using Chi-square
test (n = 5–8 per group). *P<0.05, **P<0.01 vs. SERCA2a KOmice.
doi:10.1371/journal.pone.0139715.g002
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predominant feature. Hypothetically, triggers of such systemic inflammatory states and/or the
consequence of systemic inflammation may impact the natural progression of HF. In this
study we show that persistent systemic TLR9 stimulation induces increased mortality and
worsening of diastolic function in a model of diastolic HF (i.e., cardiomyocyte specific SER-
CA2a KO). These features were accompanied by enhanced monocyte/macrophage infiltration
and expression of inflammatory cytokines, and a trend towards increased collagen deposition
within the failing myocardium, as well as increased levels of monocytes and T cells in periph-
eral blood in TLR9 stimulated SERCA2a KO mice. Our findings suggest a link between sys-
temic inflammation and worsening of diastolic HF, potentially involving increased monocyte/
macrophage driven myocardial inflammation.
Fig 3. Increased number of MAC-2 positive cells in TLR9 stimulatedmouse hearts. (A) Photos taken with 40x objective (scale bar 50μm). (B) MAC-2
image based quantification of MAC-2 positive cells. Statistics were done using MannWhitney U- test (n = 5–8 per group). Lines and error bars are mean
±SEM. *P<0.05, **P<0.01 vs. SERCA2a KOmice. #P<0.05 vs. control with same intervention.
doi:10.1371/journal.pone.0139715.g003
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Our major finding was that SERCA2a KO mice challenged with sustained TLR9 stimulation
died prematurely accompanied by worsening of diastolic dysfunction compared with PBS
treated SERCA2a KO mice. We believe our data supports this being a consequence of cardiac
death due to 1) no mortality in TLR9 stimulated control mice and 2) clear evidence of deterio-
rated cardiac dysfunction in TLR9 stimulated SERCA2a KO mice. Meticulous analyses of car-
diac function by echocardiography and PC-MRI lead us to conclude that the predominant
cause of TLR9 stimulated aggravation of HF is worsening of diastolic function. The SERCA2a
KO mice in the late phases do display evidence of systolic impairment, but no significant wors-
ening of this dysfunction could be seen upon sustained TLR9 stimulation. In fact, CpG B stim-
ulated SERCA2a KO mice showed higher LVEF in an early phase. LVFS and LVEF are known
to be rather insensitive parameters to smaller alterations in systolic dysfunction, whereas
PC-MRI is considered a more sensitive method [26], in particular by measurement of LV lon-
gitudinal strain. Thus, the SERCA2a KO mice in addition to diastolic dysfunction, had systolic
dysfunction.
The worsened diastolic HF could be a consequence of impaired active relaxation and/or pas-
sive recoil of the myocardium [15]. Our model of diastolic HF is one predominately conveyed
by interference in active relaxation [17]. Accordingly, it is reasonable to suggest that the prema-
ture deaths of TLR9 stimulated mice are a consequence of an accelerated reduction in diastolic
Fig 4. Quantitative PCR on left ventricle myocardial tissue of mice with HF 8 weeks after SERCA2a gene excision and 4 weeks after initiation of
sustained TLR9 stimulation. (A) CXCL2, Chemokine C-X-C motif ligand 2 (B) CXCL10, Chemokine C-X-C motif ligand 10 (C) MCP-1, Monocyte
chemotactic protein-1 (D) TNF, Tumor necrosis factor. Statistics were done using MannWhitney U- test (n = 7–12 per group). Data are mean±SEM. *P<0.05,
**P<0.01 vs. SERCA2a KO. #P<0.05, ## P<0.05 vs. control with same intervention.
doi:10.1371/journal.pone.0139715.g004
Chronic TLR9 Activation Aggravates Diastolic Heart Failure
PLOS ONE | DOI:10.1371/journal.pone.0139715 October 13, 2015 12 / 19
Fig 5. Hydroxyproline analysis by HPLC andmRNA gene expressions of Collagen I and III
demonstrated a trend towards increased collagen deposition in TLR9 stimulated SERCA2a KO
hearts. (A) Collagen (μg/ml dry weight) (B) Collagen I (C) Collagen III. Statistics were done using Mann
Whitney U- test (n = 7 per group except n = 5 in CpG SERCA2a KO group). Lines and error bars are mean
±SEM. **P<0.01 vs. SERCA2a KOmice. ###P<0.0001 vs. controls with same intervention.
doi:10.1371/journal.pone.0139715.g005
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Fig 6. Flow cytometry of CD11b, CD3 and LY6G stained circulating blood cells showed alterations in
distribution of cells. (A) CD11b-APC positive cells (B) CD3-FITC positive cells and (C) LY6G-PE positive
cells. Statistics were done using MannWhitney U- test (n = 6–12 per group). Lines and error bars are mean
±SEM. *P<0.05 vs. SERCA2a KOmice. ###P<0.001 vs. control with same intervention.
doi:10.1371/journal.pone.0139715.g006
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function. Our finding of a trend towards increased tissue fibrosis in CpG B treated mice, as
Fig 7. Organ weights of mice at 8 weeks after SERCA2A gene excision and 4 weeks after initiation of
sustained TLR9 stimulation. (A) Lung weight (mg)/TL (B) Liver weight (mg)/TL (C) Spleen weight (mg)/TL.
TL, tibia length (mm). Statistics were done MannWhitney U- test (n = 7–12 per group). Data are meanxSEM.
*P<0.05, **P<0.01, **P <0.001 vs. SERCA2a KO. #P<0.05 vs. control with same intervention.
doi:10.1371/journal.pone.0139715.g007
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well as increased inflammatory responses, suggests that the reduced diastolic function also
involves deteriorated passive relaxation. However, the mechanisms leading to deteriorated dia-
stolic heart failure are still elusive, as our model of chronic systemic TLR9 stimulation does not
allow discrimination between cardiac TLR9 stimulation towards the indirect effects of systemic
TLR9 stimulation and subsequent effects on the heart caused by the following systemic inflam-
matory response.
Both scenarios are possible. On the one hand, stimulation of cardiac TLR9 does impact con-
tractile performances on the cardiac myocyte level [27,28]. No studies however, have specifi-
cally addressed the significance of TLR9 stimulation on active relaxation. Still, a recent study
linked non-canonical TLR9 signaling to SERCA2 function through CpG B induced reduction
of SERCA2 function and cell survival [29]. On the other hand, stimulation of both cardiac and
non-cardiac TLR9 will elicit signaling leading to activation of NF-kB and Interferon regulatory
factor 3/7 (IRF3/7), both resulting in release of various inflammatory cytokines and chemo-
kines. Indeed, in the present study we found that the impairment of diastolic function was asso-
ciated with increased myocardial inflammation with enhanced expression of inflammatory
cytokines and increased infiltration of monocytes/macrophages. This could point to an inflam-
matory phenotype within the myocardium that affects its function.
While systemic administration of TLR9 agonist has been shown to attenuate myocardial
hypertrophy and dysfunction in both isoproterenol and pressure overload-induced cardiomy-
opathy [3,17], we found worsening of diastolic function in a model of diastolic HF with no
attenuating effects on systolic function. The studies of Yang and Velten, however, have designs
that substantially differ from our study, as their mode of TLR9 stimulation was restricted to the
time period prior to intervention, potentially preconditioning the heart to myocardial damage.
Also, it is not inconceivable that systemic TLR9 activation have different effects on systolic and
diastolic HF. HF with preserved systolic function is an increasing problem in clinical cardiol-
ogy. About 50% of patients with HF have preserved ejection fraction (HFpEF), which is espe-
cially common in elderly people with highly prevalent co-morbid conditions [30,31]. Our
findings may suggest a role for TLR9 activation in the pathogenesis of this disorder.
In the present study we found that systemic TLR9 activation affected various organ systems.
In lungs, only minor effects were seen with sustained TLR9 stimulation. In contrast, the inflam-
matory responses seen in liver were predominately driven by TLR9 stimulation with no addi-
tional effect of diastolic HF. In the myocardium, however, there was a tendency towards
increased inflammatory responses in the TLR9 stimulated SERCA2a KO mice as compared to
the pure SERCA2a KO and TLR9 stimulated control mice, indicating an interaction between
TLR9 and HF within the myocardium. Such an interaction was even more evident in periph-
eral blood. While the levels of T cells and monocytes were attenuated upon TLR9 stimulation
in control mice, the proportion of these cells increased in TLR9 stimulated SERCA2a KO mice.
Recent studies suggest an important role for spleen-derived monocytosis with subsequent
increased cardiac macrophage infiltration during myocardial remodeling following an ischemic
event [32]. It has also been proposed that a similar mechanism could be in play during HFpEF
[33]. If so, TLR9-driven mechanisms could be involved, although this will have to be proved in
forthcoming studies.
Even though our data demonstrates that sustained systemic TLR9 stimulation aggravates
diastolic HF in our model of gene-targeted diastolic HF, there are several limitations as to
mechanistic explanations of causality, as well as extrapolations to clinical inflammatory disease
states and other HF conditions. First, our pharmacological inflammatory model does not allow
discrimination between effects caused by direct cardiac TLR9 stimulation to that of indirect
effects mediated by systemic inflammation. Second, although several systemic inflammatory
conditions have disturbances in the innate immune system as important features, and some of
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these again specifically encompassing distorted TLR9 signaling [34], sustained TLR9 stimula-
tion does not necessarily represent a clinically relevant inflammatory condition. Finally, the
cardiac myocyte SERCA2a KO model does not adequately represent the molecular basis for, or
the clinical features of, diastolic HF.
With the above-mentioned limitations, our study suggests a link between systemic TLR9
activation and diastolic HF, involving systemic inflammation and increased monocyte/macro-
phage infiltration within the failing myocardium. These data do provide a platform for future
investigations studying both systemic and myocardial restricted TLR9 activation combined
with various models of experimental HF.
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